Core Viewpoint - The strategic partnership between Giant Bio and Nordberg Medical aims to leverage Giant Bio's patented recombinant collagen technology for global market expansion in the medical aesthetics sector, indicating a shift towards international growth opportunities [2][5][10]. Financial Performance - In the first half of the year, Giant Bio reported revenue of 31.13 billion yuan, a year-on-year increase of 22.52%, and a net profit attributable to shareholders of 11.82 billion yuan, up 20.23% [7]. - Despite positive growth, the revenue and net profit growth rates have slowed compared to previous years, where growth rates exceeded 40% [7]. - The company's gross margin for the first half of the year was 81.68%, down from previous years' figures of 85.11%, 84.14%, and 82.4% [7]. Strategic Developments - The partnership with Nordberg Medical allows Giant Bio to utilize the latter's established global marketing and sales network, facilitating quicker entry into international markets [5][10]. - Giant Bio received a medical device registration certificate for its recombinant type I α1 collagen product, marking a significant step into the professional medical sector [10][12]. Market Position and Competition - The competitive landscape in the recombinant collagen market is intensifying, with companies like Huaxi Bio and Jinbo Bio also making significant advancements [10][11]. - Jinbo Bio has established a lead in the market with multiple approved medical device registrations, highlighting Giant Bio's relatively slower progress in this area [11][12]. Stock Performance and Market Sentiment - Giant Bio's stock has seen a significant decline, dropping approximately 60% from its peak of 85.14 HKD per share earlier in the year, now trading at 34.56 HKD [12]. - The company announced a share buyback plan to repurchase up to 10% of its issued shares, reflecting confidence in its long-term strategy and growth potential [12].

2025.12. 29 本文字数：1670，阅读时长大约3分钟 作者 | 第一财经 魏中原 这些现象引发了市场对科技企业"重融资、轻研发"的担忧。需要厘清的是，问题不在于资本市场制度 本身，而在于执行与监督环节的缺失。以科创板为例，该板块的创新性制度设计的初衷是通过市场化 机制引导资金流向真正需要的硬科技研发，推动科技企业做大做强。 创新政策带来了溢价，使得市场给予的部分科技企业高估值与超募资金，本质上是社会对科技企业突 破技术"卡脖子"的深切期待，是国家为支持创新提供的特殊政策支持。这份政策支持的初心，始终指 向"研发突破"而非"理财躺赚"。 笔者认为，当前科技型上市公司募资理财现象背后有三方面深层原因。 企业层面，部分企业对研发周期和资金消耗速度缺乏准确评估，担心资金投入过快导致"烧钱"压力过 大，选择"慢撒网、稳推进"策略。 政策支持科技企业上市的初心，始终是为中国科技突破"卡脖子"技术提供资本支撑，为国家科技自立 自强注入源头活水。科创板等上市板块的设立，是国家推动科技创新、实现产业自主可控的战略性制 度安排。这一制度设计本身具有前瞻性与积极意义，其目标在于引导资本"脱虚向实"，推动科技企业 真正在研 ...

Core Viewpoint - The initial intention of supporting technology companies to go public is to provide capital support for China's technological breakthroughs in critical areas, injecting vital resources for national technological self-reliance [1][2] Group 1: Current Issues - The phenomenon of "IPO for financial management" has evolved from isolated cases to a systemic behavior among technology companies, raising concerns about their commitment to research and development [1][2] - Companies like Moer Thread and Huahong Semiconductor have been reported to allocate substantial IPO funds (e.g., 7.5 billion yuan and over 20 billion yuan respectively) into low-risk financial products instead of investing in production and R&D [1] - This trend of diverting funds from essential projects to financial products distorts market resource allocation efficiency and undermines the integrity of the capital market [1] Group 2: Underlying Reasons - At the enterprise level, some companies lack accurate assessments of R&D cycles and funding consumption rates, leading them to adopt a cautious approach to funding allocation [3] - The market environment has seen inflated valuations in the primary market, prompting companies to rationalize their financial management strategies to maintain high valuations [4] - The responsibility of intermediary institutions has been lacking, as they fail to effectively supervise the use of raised funds, which should be directed towards actual projects rather than financial management [4] Group 3: Successful Examples - The design of the Sci-Tech Innovation Board has successfully supported the growth of several companies in sectors like semiconductors and biomedicine, with examples including SMIC and Zhongwei Technology, which have achieved technological breakthroughs and market value growth through effective fundraising [4] Group 4: Recommendations for Improvement - Strengthening the responsibility of intermediary institutions by incorporating continuous supervision into core assessment metrics and implementing thorough oversight of financial management behaviors [5] - Optimizing information disclosure requirements for companies to provide detailed funding usage plans and R&D progress, establishing a correlation assessment system between funding use and technological breakthroughs [5] - Creating positive incentives for companies with high R&D investment ratios and significant technological breakthroughs by offering green channels for refinancing, fostering a virtuous cycle between R&D investment, technological breakthroughs, and market value [5] Group 5: Conclusion - The development of the capital market requires professionalism and accountability from "gatekeepers," as well as a commitment from technology companies to their original intentions, ensuring that the Sci-Tech Innovation Board remains focused on strengthening China's technological capabilities rather than merely generating profits [6]

Group 1 - The core intention of policies supporting technology companies' IPOs is to provide capital support for breakthroughs in critical technologies and to inject fresh resources for national technological self-reliance [1][2] - The establishment of the Sci-Tech Innovation Board and other listing platforms is a strategic arrangement aimed at promoting technological innovation and achieving industrial autonomy [1][2] - There is a growing concern in the market regarding technology companies focusing more on financing rather than research and development, as evidenced by the trend of companies using IPO funds for financial management instead of investing in production and R&D [2][3] Group 2 - The phenomenon of using IPO funds for financial management has evolved from isolated cases to a systemic behavior among technology companies, particularly in the semiconductor sector [1][2] - The lack of accurate assessment of R&D cycles and funding consumption speed at the enterprise level has led some companies to adopt a cautious approach, opting for a "slow and steady" strategy [3][4] - The high valuations in the primary market have inflated financing expectations, prompting some companies to rationalize their use of funds to maintain these valuations [4] Group 3 - The responsibility of intermediary institutions has been lacking, as they fail to effectively supervise the use of raised funds, which should be directed towards actual projects rather than financial products [4] - The successful design of the Sci-Tech Innovation Board has led to the growth of several companies in sectors such as semiconductors and biomedicine, demonstrating the potential for technology breakthroughs and market value growth through proper funding [4][5] Group 4 - Recommendations for improving the mechanism include strengthening the responsibilities of intermediary institutions, optimizing information disclosure, and establishing positive incentives for companies with significant R&D investments [5][6] - A clear connection between funding usage and technological breakthroughs should be established to enhance transparency for investors [5] - The development of the capital market requires both professional oversight from "gatekeepers" and a commitment from technology companies to their original mission of driving technological advancement [6]

Core Viewpoint - The medical beauty sector experienced a decline of 0.97% on December 29, with Ai Meike leading the drop, while the overall Shanghai Composite Index rose slightly by 0.04% [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3965.28, and the Shenzhen Component Index closed at 13537.1, down by 0.49% [1] - The medical beauty sector's individual stock performance showed varied results, with *ST Meigu leading with a rise of 5.10% to a closing price of 3.71, while Ai Meike fell by 2.29% to 141.03 [1] Group 2: Capital Flow - The medical beauty sector saw a net outflow of 74.18 million yuan from main funds, while retail investors contributed a net inflow of 29.66 million yuan [1] - Individual stock capital flow indicated that Ai Meike had a significant net outflow of 74.86 million yuan from main funds, despite a net inflow of 36.80 million yuan from retail investors [2]

Index Performance - The Hang Seng Index (HSI) closed at 25,819, reflecting a 0.2% increase for the day and a 28.7% increase year-to-date (YTD) [2] - The MSCI Hong Kong index rose by 0.4% to 13,921, with a YTD increase of 31.8% [2] - The KOSPI index showed significant growth, up 71.2% YTD, closing at 4,109 [2] Commodity Price Performance - Gold prices increased by 70.7% YTD, closing at $4,479 per ounce [3] - Copper prices rose by 37.6% YTD, reaching $12,061 per ton [3] - Brent Crude oil prices decreased by 12.7% YTD, closing at $62 per barrel [3] Key Macro and Earnings Releases - China's industrial profits year-to-date showed a modest increase of 1.9% despite a year-on-year decline of 5.5% [4] - The Manufacturing PMI for China was reported at 49.2, slightly below the consensus of 49.3 [4] - The Non-manufacturing PMI for China was at 49.5, also below the expected 49.7 [4] Hainan Free Trade Policy Insights - Over 6,600 goods are now exempt from tariffs in Hainan, which is expected to enhance value-added processing and lower manufacturing costs [6] - The Hainan Free Trade Port (HFTP) is viewed as a long-term positive for industries rather than a short-term boost [6] - Investors are advised to focus on consumer companies with established operations in Hainan, such as CTG Duty Free and Mixue Group [6]

摘要 创建公司推出交联重组胶原蛋白填充剂，采用独特 474 个氨基酸序列， 提供多种规格预灌封注射器包装，旨在与现有非交联产品及部分动物来 源胶原蛋白市场竞争，凭借即刻维持时间和形态优势，有望成为微整形 领域新选择，但市场表现需进一步观察。 业内普遍认为创建公司的交联技术成熟，安全性是关注点，消费者态度 复杂，期望长效但对潜在风险谨慎。机构推荐和安全性报告是消费者接 受的关键。该技术自主研发，已应用于疫苗等领域，关键在于杂质控制 和工艺流程管理，需持续改进生产工艺及严格质量控制。 创建公司医美团队月白知己由张笑红领导，拥有丰富的皮肤科产品代理 经验和客户资源，产品主要通过代理商渠道销售，覆盖皮肤科和部分注 射科室。未来大型连锁倾向成熟品牌，新氧倾向独家定制，中小机构倾 向低成本引流产品。 重组胶原蛋白被视为下一个潜力市场，未来将有多种类型和规格产品获 批。序列越长风险越高，需权衡序列长度与安全性。短序列在提纯和生 产中更简便，更具成本优势。非天然片段的引入主要为方便生产和降低 成本，实际效果需临床验证。 Q&A 创建公司最近获得的三型胶原蛋白证书有哪些特别之处？它在市场运营中可能 会如何定位和推广？ 创建公司 ...

Core Insights - Daxing Biopharmaceutical Industry Base has achieved significant milestones, including being recognized as a national-level "Green Industrial Park" and a five-star national new-type industrialization demonstration base, with plans for expansion and development in the biopharmaceutical sector [1][2][8] Group 1: Development Milestones - In 2021, Daxing Biopharmaceutical Industry Base was approved for a 9.1 square kilometer expansion, marking its entry into the trillion-level industrial park category [1] - The base was awarded the title of "Green Industrial Park" in 2022 and has been recognized for its innovative development strategies [1][2] - The construction of the new campus for Capital Medical University commenced in 2023, enhancing the collaborative innovation framework of "medical education, research, and production" [1][8] Group 2: Expansion Projects - The first industrial land project in the southern expansion area, the Ande Medical Health Industry Park, broke ground in February 2025, with a total investment of approximately 300 million yuan [7] - The northern expansion area, covering 5.5 square kilometers, focuses on living and service facilities, with the new campus of Capital Medical University as a key project [8] - During the "14th Five-Year Plan" period, the base completed 12 transactions for industrial land, emphasizing high-standard planning before construction [8] Group 3: Industry Focus and Innovation - The base has established a "3+5" industrial development roadmap, focusing on traditional Chinese medicine, vaccines, and high-end medical devices, while also exploring emerging fields like cell and gene therapy [10][11] - Daxing has become a hub for vaccine production, housing leading companies in the sector, and has transitioned from "following innovation" to "original breakthroughs" [10] - The base is also strengthening its position in high-end medical devices, with advancements in surgical robots and innovative medical implants [11] Group 4: Service and Support for Enterprises - Daxing Biopharmaceutical Industry Base provides comprehensive services for enterprises, including project site selection, business registration, environmental assessments, and policy applications [14] - A one-stop service platform has been established, integrating government services and industry resources, which has facilitated over 26,000 services to enterprises [14] - The base has organized various events to enhance collaboration and visibility for enterprises, leading to successful international market expansions for over 20 companies [15] Group 5: Future Outlook - The base aims to further optimize its industrial system by focusing on the "3+2+N" model, which includes strengthening existing industries and exploring new potential sectors [17] - The "15th Five-Year Plan" emphasizes the development of new productive forces and high-quality economic growth, aligning with Daxing's strategic goals [17] - Daxing Biopharmaceutical Industry Base is committed to continuing its role as a key player in the biopharmaceutical industry, with plans for further expansion and innovation [17]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index declining by 1.1% from December 19 to December 26, 2025, which is weaker than the market performance [4][5]. - Lin Qingxuan is set to lead the high-end domestic essence oil sector with its upcoming IPO on December 30, 2025, planning to issue 13.9665 million H shares. The company has shown significant growth, with revenue projected to increase from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a compound annual growth rate (CAGR) of 32.7% [4][10]. - The report highlights the strong performance of Yiwang Yichuang (300792SZ) in the e-commerce agency sector, leveraging AI to enhance operational efficiency and revenue potential [11][12]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the market, with specific indices showing declines: the Shenwan Cosmetics Index fell by 1.3%, and the Shenwan Personal Care Index decreased by 1.0% [4][5]. Key Company Developments - Lin Qingxuan's IPO is anticipated to bolster its market position, with a focus on high-end skincare products. The company has achieved a market share of 1.4% in the high-end skincare segment and ranks 10th in the anti-wrinkle product market with a 2.2% share [10]. - Yiwang Yichuang's business model is robust, with a comprehensive coverage of consumer goods categories and deep collaboration with Alibaba, positioning it well for future growth [11][12]. Market Trends - The report notes a recovery in the e-commerce agency sector, driven by increased demand for brand representation on platforms like Alibaba, with a notable rebound in traffic [12][13]. - The overall retail sales of cosmetics in China showed a growth of 4.8% year-on-year for the first 11 months of 2025, with November alone seeing a 6.1% increase, aided by promotional events [18][20]. Regulatory and Product Innovations - Jiangsu Chuangjian Medical Technology's collagen implant product received approval from NMPA, indicating ongoing innovation in the medical beauty sector [22]. - The report also mentions the investment by L'Oréal in a Chinese pharmaceutical company, marking a significant move into the skin health sector [25].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a transformation with a focus on emotional consumption and innovative product offerings, particularly in the jewelry and cosmetics sectors [6][33] - Companies like潮宏基 and毛戈平 are leveraging multi-channel strategies to enhance brand visibility and product sales, indicating a strong market presence [26][31] Summary by Sections Retail Market Overview - The retail index closed at 2462.73 points, with a weekly increase of 0.16%, underperforming the Shanghai Composite Index, which rose by 1.88% [5][15] - The retail sector has seen a year-to-date increase of 10.00%, lagging behind the Shanghai Composite Index's 18.26% rise [15][19] Company Highlights - **潮宏基**: Achieved a revenue of 62.37 billion yuan in the first three quarters of 2025, up 28.4% year-on-year, with a net profit of 3.17 billion yuan, reflecting a 0.3% increase [42] - **毛戈平**: Launched the "琉光赋活" skincare series, set to debut on January 1, 2026, focusing on high-end skincare needs [31] - **周大福**: Reported a revenue of 389.86 billion HKD for FY2026H1, a slight decrease of 1.1%, but with a net profit increase of 0.1% [39] Investment Themes - **Gold and Jewelry**: Focus on brands with differentiated product offerings and consumer insights, recommending潮宏基 and老铺黄金 as key players [6][33] - **Offline Retail**: Emphasis on companies adapting to market changes, with recommendations for永辉超市 and爱婴室 [6][33] - **Cosmetics**: Highlighting brands that innovate with emotional value and safe ingredients, recommending毛戈平 and珀莱雅 [6][34] - **Medical Aesthetics**: Targeting differentiated product manufacturers and expanding medical aesthetic chains, with recommendations for爱美客 and科笛-B [6][34]